CA2936691A1 - Enolase 1 (eno1) compositions and uses thereof - Google Patents

Enolase 1 (eno1) compositions and uses thereof Download PDF

Info

Publication number
CA2936691A1
CA2936691A1 CA2936691A CA2936691A CA2936691A1 CA 2936691 A1 CA2936691 A1 CA 2936691A1 CA 2936691 A CA2936691 A CA 2936691A CA 2936691 A CA2936691 A CA 2936691A CA 2936691 A1 CA2936691 A1 CA 2936691A1
Authority
CA
Canada
Prior art keywords
subject
blood glucose
enol
eno1
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2936691A
Other languages
English (en)
French (fr)
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K. Vishnudas
Stephane Gesta
Enxuan Jing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BERG LLC
Original Assignee
BERG LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BERG LLC filed Critical BERG LLC
Publication of CA2936691A1 publication Critical patent/CA2936691A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
CA2936691A 2014-01-13 2015-01-13 Enolase 1 (eno1) compositions and uses thereof Abandoned CA2936691A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461926913P 2014-01-13 2014-01-13
US61/926,913 2014-01-13
US201462009783P 2014-06-09 2014-06-09
US62/009,783 2014-06-09
US201562100881P 2015-01-07 2015-01-07
US62/100,881 2015-01-07
PCT/US2015/011275 WO2015106295A2 (en) 2014-01-13 2015-01-13 Enolase 1 (eno1) compositions and uses thereof

Publications (1)

Publication Number Publication Date
CA2936691A1 true CA2936691A1 (en) 2015-07-16

Family

ID=53524434

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2936691A Abandoned CA2936691A1 (en) 2014-01-13 2015-01-13 Enolase 1 (eno1) compositions and uses thereof
CA2936694A Abandoned CA2936694A1 (en) 2014-01-13 2015-01-13 Enolase 1 (eno1) compositions and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2936694A Abandoned CA2936694A1 (en) 2014-01-13 2015-01-13 Enolase 1 (eno1) compositions and uses thereof

Country Status (14)

Country Link
US (4) US10188708B2 (enExample)
EP (2) EP3094341B1 (enExample)
JP (2) JP6644006B2 (enExample)
KR (1) KR20160106175A (enExample)
CN (3) CN112336851A (enExample)
AU (2) AU2015204452A1 (enExample)
BR (1) BR112016016153A2 (enExample)
CA (2) CA2936691A1 (enExample)
EA (1) EA201691420A1 (enExample)
HK (1) HK1231425A1 (enExample)
IL (1) IL246720A0 (enExample)
MX (1) MX2016009102A (enExample)
SG (1) SG11201605698XA (enExample)
WO (2) WO2015106296A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
US20160375113A1 (en) * 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
JP7042755B2 (ja) 2016-06-05 2022-03-28 バーグ エルエルシー 患者層別化及び潜在的バイオマーカー同定のためのシステム及び方法
CN107991493B (zh) * 2017-11-22 2020-03-31 中国医科大学附属第一医院 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用
CN112111462B (zh) * 2020-09-14 2022-08-23 兰州大学 烯醇化酶eno1单克隆抗体及其应用
KR20240099206A (ko) * 2021-11-26 2024-06-28 후닐라이프 바이오테크놀로지, 인코포레이트 인간 질병을 치료하기 위해 세포외 알파-에놀라제를 표적화하여 해당과정을 조절하는 방법
CN114533902A (zh) * 2022-02-28 2022-05-27 河南师范大学 一种过表达lrrc15基因的质粒载体及其制备方法和应用
CN115786317B (zh) * 2022-12-12 2026-03-20 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233126T2 (de) 1992-09-25 2004-04-15 Neorx Corp., Seattle Therapeutischer inhibitor der vaskulären glatten muskelzellen
BR9509438A (pt) 1994-10-25 1997-12-23 Immulogic Pharma Corp Composições e tratamento para a esclerose múltipla
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US20030044795A1 (en) 1996-09-06 2003-03-06 Inger Byrajalsen Biochemical markers of the human endometrium
US7078375B1 (en) * 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US6329501B1 (en) 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
WO2001016323A2 (en) 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CA2382030A1 (en) 1999-09-01 2001-03-08 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2001030973A2 (en) 1999-10-25 2001-05-03 Princeton University Genetic sequences associated with neural cell proliferation and disease
US20030166549A1 (en) 2000-02-02 2003-09-04 Klaus Schughart Targeting peptides
US20030203372A1 (en) 2000-12-08 2003-10-30 Ward Neil Raymond Analysis method
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
US20040058326A1 (en) 2001-07-27 2004-03-25 Brooksbank Robert Alan Identification and use of molecules implicated in pain
US20050191627A1 (en) 2001-09-28 2005-09-01 Incyte Corporation Enzymes
WO2003064501A1 (en) * 2002-01-31 2003-08-07 Clarke Slemon Conformationally restricted compounds as dendrimer cores
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
JP2004081111A (ja) 2002-08-27 2004-03-18 Yamaguchi Technology Licensing Organization Ltd 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
CN101518535A (zh) * 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US20040219572A1 (en) 2002-12-17 2004-11-04 Jie Chen Specific markers for pancreatic cancer
WO2004061088A2 (en) 2002-12-30 2004-07-22 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US20060263336A1 (en) 2003-03-24 2006-11-23 Caplan Arnold I Cell targeting methods and compositions
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005073621A (ja) 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
CA2540529C (en) 2003-10-03 2012-03-13 Vib Vzw Means and methods for the recruitment and identification of stem cells
US8133733B2 (en) * 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
JP2006528361A (ja) 2004-07-06 2006-12-14 クンイル ファーマシューティカル カンパニー リミテッド アルドラーゼを含む網膜血管疾患診断用組成物およびその診断方法
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
WO2006073254A1 (en) 2005-01-03 2006-07-13 Sook-Yeong Jeon Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
EP2121747A2 (en) 2006-07-27 2009-11-25 Oxford Genome Sciences (UK) Limited New protein isoforms and uses thereof
WO2008037792A1 (en) 2006-09-29 2008-04-03 Ribovax Biotechnologies Sa Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma
US20100047256A1 (en) 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
WO2008134761A2 (en) 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
CN103212085A (zh) 2007-07-12 2013-07-24 普罗森那技术公司 用于使化合物靶向多种选定器官或组织的分子
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
JP5429707B2 (ja) 2008-03-27 2014-02-26 国立大学法人群馬大学 微粒子およびその製造方法
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
ES2524475T3 (es) 2008-07-18 2014-12-09 Hill's Pet Nutrition, Inc. Composiciones y métodos para tratar trastornos asociados con animales con sobrepeso
EP2194382A1 (en) 2008-12-03 2010-06-09 Universität des Saarlandes An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies
US20110269665A1 (en) * 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
US20120309684A1 (en) 2009-11-30 2012-12-06 Isis Innovation Limited Conjugates for delivery of biologically active compounds
WO2011072290A2 (en) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
WO2011147981A2 (en) 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
EP2707018B1 (en) 2011-05-10 2015-11-04 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of autoimmune diseases
GB201113814D0 (en) 2011-08-10 2011-09-28 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
AU2012300633B2 (en) 2011-08-30 2017-04-27 United Kingdom Research And Innovation Cell- penetrating peptides having a central hydrophobic domain
ES2746058T3 (es) 2011-12-14 2020-03-04 Univ Texas Biomarcadores colaterales de inactivación génica y dianas para el tratamiento del cáncer
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
CN104780911A (zh) 2012-10-30 2015-07-15 粒子科学有限公司 具有靶向部分的药物递送粒子制剂
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
US20160375113A1 (en) 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
EP3322405A4 (en) 2015-07-16 2019-01-23 Berg LLC ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF

Also Published As

Publication number Publication date
MX2016009102A (es) 2016-09-09
CN106659766B (zh) 2025-03-28
US10188707B2 (en) 2019-01-29
EP3094379A4 (en) 2017-06-28
US20150361409A1 (en) 2015-12-17
WO2015106296A8 (en) 2015-08-20
AU2015204452A1 (en) 2016-08-11
SG11201605698XA (en) 2016-08-30
WO2015106296A1 (en) 2015-07-16
EP3094341A4 (en) 2017-11-01
US20150359861A1 (en) 2015-12-17
BR112016016153A2 (pt) 2017-12-12
EP3094341A1 (en) 2016-11-23
WO2015106295A3 (en) 2015-11-05
AU2015204451A1 (en) 2016-07-28
CN106102835B (zh) 2020-11-03
EA201691420A1 (ru) 2016-12-30
HK1231394A1 (en) 2017-12-22
CN106102835A (zh) 2016-11-09
JP6644006B2 (ja) 2020-02-12
CA2936694A1 (en) 2015-07-16
JP2017509690A (ja) 2017-04-06
US20190307863A1 (en) 2019-10-10
IL246720A0 (en) 2016-08-31
CN106659766A (zh) 2017-05-10
JP6629234B2 (ja) 2020-01-15
HK1231425A1 (zh) 2017-12-22
WO2015106295A2 (en) 2015-07-16
US11224641B2 (en) 2022-01-18
JP2017508000A (ja) 2017-03-23
KR20160106175A (ko) 2016-09-09
EP3094379A2 (en) 2016-11-23
US10188708B2 (en) 2019-01-29
EP3094341B1 (en) 2019-10-02
US20190307864A1 (en) 2019-10-10
CN112336851A (zh) 2021-02-09

Similar Documents

Publication Publication Date Title
US11224641B2 (en) Enolase 1 (ENO1) compositions and uses thereof
US20230078745A1 (en) Blood Biomarkers and Diagnostic Methods for Small Vessel Diseases
CN102317783A (zh) 作为胃肠癌的标记的ykl-40
AU2014366827A1 (en) Method of diagnosis and treatment
JP2019506374A (ja) メトホルミンのバイオマーカーとしての増殖分化因子１５
JP5863660B2 (ja) Ｇｓｔｐ１の使用
JP2024037767A (ja) 改変型線維芽細胞成長因子２１（ｆｇｆ－２１）を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の処置方法
EP4051702B1 (en) Theranostics for hypertension induced myocardial microbleeds
JP5739433B2 (ja) 血中インスリン抵抗性及び糖尿病マーカープログラニュリン、採血試料中のプログラニュリン濃度の分析方法、及び、インスリン抵抗性を改善及び糖尿病を改善又は抑制する物質のスクリーニング方法
HK1231394B (en) Enolase 1 (eno1) compositions and uses thereof
Brunchault Identification of biomarkers using-omics approach for the early detection of chronic kidney disease and its complications
WO2025155991A2 (en) Predictive biomarkers for response to coenzyme q10 treatment in pancreatic cancer
CA2923661A1 (en) Nuclear stress response in motor neuron disease and other neurological diseases
HK40016117A (en) A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
Lu Developing blood-based biomarkers of disease progression in Amyotrophic Lateral Sclerosis
HK40075067A (en) Enhancing blood-brain barrier drug transport by targeting alpl
WO2014113519A1 (en) Using galectin-binding carbohydrates as predictors of melanoma progression and metastasis

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831